Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH708980 and AmBisome in Visceral Leishmaniasis
NCT01437020Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of SCH708980 in visceral leishmaniasis (VL) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and tolerability of a single IV infusion of SCH708980 in combination with AmBisome at Day 8. Status: withdrawn.
02
Drugs
SCH708980
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT01437020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01437020.